Ads
related to: statins don't increase survivability due to inflammation syndrome and stress
Search results
Results From The WOW.Com Content Network
Statin-associated autoimmune myopathy (SAAM), also known as anti-HMGCR myopathy, is a very rare form of muscle damage caused by the immune system in people who take statin medications. [1] However, there are cases of SAAM in patients who have not taken statin medication, and this can be explained by the exposure to natural sources of statin ...
The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP). JUPITER was the first clinical trial to indicate that statin therapy may provide benefit to patients with low-to-normal LDL levels and no known cardiovascular disease.
The statin use may require that the warfarin dose be changed, as some statins increase the effect of warfarin. [ 64 ] The most important adverse side effects are muscle problems, an increased risk of diabetes mellitus , and increased liver enzymes in the blood due to liver damage .
For premium support please call: 800-290-4726 more ways to reach us
Researchers say women with heart disease are less likely to be prescribed cholesterol-lowering medications such as statins than men with the same conditions ... with a chronic cardiac syndrome ...
Alternative uses for statins for other health conditions are an ongoing area of research. Effects of statins on inflammation, cancer. Researchers of the current study note that chronic ...
Chronic systemic inflammation (SI) is the result of release of pro-inflammatory cytokines from immune-related cells and the chronic activation of the innate immune system.It can contribute to the development or progression of certain conditions such as cardiovascular disease, cancer, diabetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease, autoimmune and neurodegenerative ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.